Premium
Phenol Glycosides with In Vitro anti‐ Helicobacter pylori Activity from Hypericum erectum Thunb
Author(s) -
Moon HyungIn,
Lee YoungChoon,
Lee JaiHeon
Publication year - 2011
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.3453
Subject(s) - glycoside , quercetin , hypericum , in vitro , helicobacter pylori , stereochemistry , phenol , flavonoid , phenols , chemistry , traditional medicine , biology , biochemistry , medicine , organic chemistry , genetics , antioxidant
To evaluate the anti‐ Helicobacter pylori activity of Hypericum erectum methanol extracts in order to provide the primary evidence for their use in clinical practice. An ethyl acetate fraction of H. erectum suspension‐cell cultures inhibited the growth of H. pylori in vitro , with a MIC 50 range of 38.7–63.2 μg/mL, comparable to metronidazole (MIC 50 = 43.2 μg/mL). To further investigate the involved active compounds of the H. erectum extracts, four phenol glycosides were isolated for the current study: quercetin‐3′‐ O‐β ‐ d ‐galactopyranoside, quercetin‐3′‐ O ‐(2′′‐acetyl)‐ β ‐ d ‐glucopyranoside, 4,6‐dihydroxy‐2‐methoxyphenyl‐1‐ O‐β ‐ d ‐glucopyranoside and 4‐hydroxy‐2,6‐dimethoxyphenyl‐1‐ O‐α ‐ l ‐rhamnopyranosyl(1–6)‐ β ‐ d ‐glucopyranoside. The MIC 50 values of 4,6‐dihydroxy‐2‐methoxyphenyl‐1‐ O‐β ‐ d ‐glucopyranoside and 4‐hydroxy‐2,6‐dimethoxyphenyl‐1‐ O‐α ‐ l ‐rhamnopyranosyl(1–6)‐ β ‐ d ‐glucopyranoside from ATCC43504 strains were 7.3 and 27.3 μg/mL, respectively. The other two phenol glycosides did not show anti‐ H. pylori activity. The results of this work suggest that H. erectum has some therapeutic potential against H. pylori infection, which could be explored for patients with gastroduodenal disorders. Copyright © 2011 John Wiley & Sons, Ltd.